Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Interventional × Aflatoxin Poisoning × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 2422 Carcinoma, Non-Small-Cell Lung 1969 Prostatic Neoplasms 1274 Colorectal Neoplasms 1132 Neoplasms 1084 Multiple Myeloma 938 Lung Neoplasms 921 Neoplasm Metastasis 883 Leukemia, Myeloid, Acute 851 Lymphoma 785 Melanoma 766 Pancreatic Neoplasms 722 Ovarian Neoplasms 702 Carcinoma, Hepatocellular 677 Stomach Neoplasms 666 Recurrence 661 Leukemia 647 Lymphoma, Non-Hodgkin 602 Leukemia, Lymphocytic, Chronic, B-Cell 576 Squamous Cell Carcinoma of Head and Neck 542 Lymphoma, Large B-Cell, Diffuse 541 Brain Neoplasms 527 Head and Neck Neoplasms 523 Precursor Cell Lymphoblastic Leukemia-Lymphoma 521 Glioblastoma 514 Carcinoma, Renal Cell 506 Rectal Neoplasms 495 Sarcoma 455 Myelodysplastic Syndromes 455 Lymphoma, Follicular 447

Interventions

sodium calcium aluminosilicate, hydrated 1 Calcium Carbonate 1 ACCS100 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01677195 2016-04-19

RDMEACCS100

Texas Enterosorbents Incorporated

Phase 2 Completed

234 enrolled 7 charts

Aflatoxin Poisoning, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡